Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Pieter R. Cullis, PhD, FRSC, FRS, OBC, OC, Director, Nanomedicines Research Group, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the FDA, the European EMA and Health Canada. Dr. Cullis has also co-founded more than 10 biotechnology companies that now employ over 500 people, has published over 400 scientific articles (h index 140) and is an inventor on over 100 patents. He has also co-founded and been Founding Scientific Director of two National Centre of Excellence networks, the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019. These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products and have given rise to numerous start-up companies. Dr. Cullis also has a strong interest in personalized medicine, having published a book entitled “The Personalized Medicine Revolution: How Diagnosing and Treating Disease Are About to Change Forever” in 2015.

Two drugs enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty has played a major role in containing the global Covid-19 pandemic with approximately 6B doses administered worldwide in 2021 and 2022.

Dr. Cullis has received many awards including the Order of Canada in 2021, the VinFuture Prize (Vietnam), the Prince Mahidol Award (Thailand), the Gairdner International Award (Canada) and the Tang Prize (Taiwan) in 2022 and the Harvey Prize (Israel) and the Killam Prize (Canada) in 2023. He was made a Fellow of the Royal Society (London) in 2023 and elected to the Canadian Medical Hall of Fame in 2024.

Dr. Lee Hood is a world-renowned scientist and has interest in technology development, cross-disciplinary biology for pioneering strategies and technologies, systems biology and data-driven Health. Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000, served as president from 2000-2017, and continues as a Professor. He is also Professor and Chief Innovation Officer at the Buck Institute for Research in Aging and CEO of the nonprofit he founded in 2021, Phenome Health, which drives data-driven health.

He received his MD from Johns Hopkins University School of Medicine (1963) and his PhD in biochemistry from Caltech (1967). Dr. Hood was a Senior Investigator for the National Cancer Institute (1967-1970). Dr. Hood was a faculty member at Caltech from 1970-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments for DNA and proteins that paved the way for the Human Genome Project’s successful sequencing of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the the first cross-disciplinary Department of Molecular Biotechnology at the University of Washington. In 2013 he pioneered data-driven health (genome/phenome analyses of individuals) with the year-long 100 person project and then the co-founding of Arivale with its 4 year recruitment of 5000 patients. He is currently pioneering data-driven health and recruiting partners to join him in fundamentally changing healthcare to optimizing wellness, facilitating healthy aging, preventing disease. In 2025 he co-founded P4Bios a peptide drug company that plans transform the pharmaceutical industry. He is currently advocating a continuation of the Human Genome Project termed the Human Phenome Initiative to catalyze a Healthcare for individuals of Wellness and Prevention. Dr. Hood has received national and international awards including the Lasker Award (1987), the Koyto Prize (2006), the National Medical of Science (2011) and the Michael Sela Prize for Biomedicine (2025). He has co-authored text books in biochemistry, immunology, cell biology, genetics and systems biology and medicine. He has co-authored two popular books, The Code of Codes (1991) and the Age of Scientific Wellness ((2023).

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Pieter R. Cullis, PhD, FRSC, FRS, OBC, OC, Director, Nanomedicines Research Group, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the FDA, the European EMA and Health Canada. Dr. Cullis has also co-founded more than 10 biotechnology companies that now employ over 500 people, has published over 400 scientific articles (h index 140) and is an inventor on over 100 patents. He has also co-founded and been Founding Scientific Director of two National Centre of Excellence networks, the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019. These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products and have given rise to numerous start-up companies. Dr. Cullis also has a strong interest in personalized medicine, having published a book entitled “The Personalized Medicine Revolution: How Diagnosing and Treating Disease Are About to Change Forever” in 2015.

Two drugs enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty has played a major role in containing the global Covid-19 pandemic with approximately 6B doses administered worldwide in 2021 and 2022.

Dr. Cullis has received many awards including the Order of Canada in 2021, the VinFuture Prize (Vietnam), the Prince Mahidol Award (Thailand), the Gairdner International Award (Canada) and the Tang Prize (Taiwan) in 2022 and the Harvey Prize (Israel) and the Killam Prize (Canada) in 2023. He was made a Fellow of the Royal Society (London) in 2023 and elected to the Canadian Medical Hall of Fame in 2024.

Dr. Lee Hood is a world-renowned scientist and has interest in technology development, cross-disciplinary biology for pioneering strategies and technologies, systems biology and data-driven Health. Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000, served as president from 2000-2017, and continues as a Professor. He is also Professor and Chief Innovation Officer at the Buck Institute for Research in Aging and CEO of the nonprofit he founded in 2021, Phenome Health, which drives data-driven health.

He received his MD from Johns Hopkins University School of Medicine (1963) and his PhD in biochemistry from Caltech (1967). Dr. Hood was a Senior Investigator for the National Cancer Institute (1967-1970). Dr. Hood was a faculty member at Caltech from 1970-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments for DNA and proteins that paved the way for the Human Genome Project’s successful sequencing of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the the first cross-disciplinary Department of Molecular Biotechnology at the University of Washington. In 2013 he pioneered data-driven health (genome/phenome analyses of individuals) with the year-long 100 person project and then the co-founding of Arivale with its 4 year recruitment of 5000 patients. He is currently pioneering data-driven health and recruiting partners to join him in fundamentally changing healthcare to optimizing wellness, facilitating healthy aging, preventing disease. In 2025 he co-founded P4Bios a peptide drug company that plans transform the pharmaceutical industry. He is currently advocating a continuation of the Human Genome Project termed the Human Phenome Initiative to catalyze a Healthcare for individuals of Wellness and Prevention. Dr. Hood has received national and international awards including the Lasker Award (1987), the Koyto Prize (2006), the National Medical of Science (2011) and the Michael Sela Prize for Biomedicine (2025). He has co-authored text books in biochemistry, immunology, cell biology, genetics and systems biology and medicine. He has co-authored two popular books, The Code of Codes (1991) and the Age of Scientific Wellness ((2023).

Dr. May Siksik is the CEO of Innovation Network Global, an organization dedicated to transforming impactful technologies into scalable, commercialized solutions that deliver measurable value. Formerly the CTO at Deep Tech Canada and leading business development and commercialization at the Quantum Algorithms Institute, Dr. Siksik has been focused on advancing both Canada’s and the global quantum innovation ecosystem.

Her contributions include founding the Healthcare Without Borders initiative, which harness quantum-enabled technologies to develop a Personalized Health Information System, supporting Canada’s National Research Council’s Applied Quantum Computing Challenge Program, and delivering transformative solutions for Indigenous communities.

Dr. Siksik is Co-Lead of the United Nations IGF Dynamic Coalition on Emerging Tech Governance & Certification, shaping policies for the responsible adoption of quantum computing, AI, blockchain, and other emerging tech. She is widely recognized for her ability to unite diverse stakeholders – including industry, academia, communities, and policymakers – to accelerate the adoption of quantum technologies. Her results-driven and holistic approach to innovation ensures that these technologies create meaningful, measurable benefits for society, industry, and underserved communities alike.

Dr. Martin Dawes is a world expert in primary care who combines research and clinical practice with over 30 years of experience. Following the completion of his PhD, he helped develop a Masters program in Evidence Based Health Care. He has directed the UK Centre for Evidence-Based Medicine in Oxford and was the head of family practice at McGill University and the University of British Columbia. He is the co-founder and scientific director  of GenXys, a medication decision support software company.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Bringing more than 35 years of experience in healthcare-related industries, Dianne currently serves as the Senior Vice President of the Government Division at Alberta Blue Cross. With a strong track record of establishing strategic and innovative partnerships, she is known for challenging the norm rather than moving with it, both at work and in her community. This coupled with her natural intuition and curiosity has led to groundbreaking initiatives in support of improved health and wellness outcomes for the communities she serves.

Dianne works closely with senior government officials—both provincial and across Canada—and a broad sector of the health industry including, pharmaceutical and medical, to foster effective working relationships. Focused on delivering quality results coupled with strong leadership, Dianne is highly engaged as both a director and board chair for various organizations and foundations. Dianne is currently actively serving as a board director for The Royal Alexandra Hospital Foundation, the Women and Children’s Health Research Institute and Edmonton Health Cities.

Dianne strives to make a positive difference in peoples’ lives. With her certification as an Executive Coach through Royal Roads University, she works to inspire and empower individuals to tackle challenges with gusto and to never accept anything less than incredible as an outcome. She looks forward to an engaging dialogue with you.

Dr. Sutcliffe is a clinical oncologist, no longer in clinical practice. He graduated from St. Bartholomew’s Hospital, University of London (1970) and trained in internal medicine, scientific research, medical and radiation oncology in the UK, South Africa, US and Canada.

He is President of Two Worlds Cancer Collaboration (2009-to date), a volunteer-based non-profit Society bridging disparities in cancer control between the higher and lesser-resourced worlds. Formerly, he was President and CEO of the Ontario Cancer Institute/ Princess Margaret Hospital (1994-96), the BC Cancer Agency (2000-09), Chair of the Governing Council of the Canadian Strategy for Cancer Control, inaugural vice-chair and past-Chair of its’ federally-funded successor, the Canadian Partnership against Cancer (2007-2012).

Past and current roles include government-funded institutions, non -governmental organizations, private sector companies, charitable foundations and international cancer control networks.

Mary is a visionary healthcare executive with 20 years of diverse senior management experience within the British Columbia provincial healthcare network, including 6 years as the CEO of Vancouver Coastal Health. She is known as a tireless advocate working to accelerate the transformation of the Canadian healthcare system into a modern and sustainable service. Mary served as an executive leader in the regionalization of British Columbia health services since its inception in 2000 and has deep experience in leveraging the benefits of integration to improve health outcomes and reduce costs. Mary possesses a proven talent for both strategic development and tactical execution that spans strategy, operations, financial and facilities management, and organizational transformation.

She has led healthcare innovation in both the clinical and technology realms by paying particular attention to the systems and culture required to drive change. She was one of two CEO co-leads responsible for implementing, at the time, the largest cross-organizational clinical software implementation in Canada. Additionally, she has a career history of success in working closely with physicians, varied health professions and frontline personnel to achieve sustained improvements in patient outcomes.

Mary has held successive executive leadership roles at Vancouver Coastal Health and Fraser Health. She also served as Associate Deputy Minister and Innovation Executive in Residence at the BC Ministry of Health and Executive Advisor within the healthcare practice of Deloitte Canada. Prior to her career in healthcare, she spent 9 years leading operations at INSEAD business school in France, and 5 years in high tech manufacturing as a plant manager in the United States. Mary’s passion and expertise in system change began with her two degrees in Industrial Engineering (B.S. and M.S.) from West Virginia University and her MBA from Harvard University.

Mary has served on many healthcare and social purpose Boards including Vancouver Foundation, Telus Community, Michael Smith Foundation, Genome BC, and Street to Home, among others. She was named one of Canada’s Top 25 CEOs by Glassdoor in 2019 and one of Canada’s Most Powerful Women in 2013 and 2014.

Stephen Samis has close to 30 years’ experience in health and health care, advancing evidence-informed health policy and population health to improve health systems and the health of Canadians.

Stephen is currently President, Samis Health Policy Consulting Inc. and works with a variety of clients on health and social policy issues, leadership development and evidence-informed decision making in the health and social sectors. He was Deputy Minister, Health and Social Services, Government of Yukon from 2017 to 2022. Before this, Stephen spent seventeen years in Ottawa where he worked in progressively senior roles for national health-related organizations including the Canadian Foundation for Healthcare Improvement (now Healthcare Excellence Canada), the Heart and Stroke Foundation of Canada and the Canadian Institute for Health Information.

Stephen is currently Co-Chair of the Appropriate Use Advisory Committee for the Canada Drug Agency and Senior Policy Advisor for the Canadian Health Leadership Network. He is active on a number of Committees and Boards, including the Alberta Primary Care Advisory Committee; the Alberta Primary Care Alliance; Alberta Innovates’ AI Advisory Committee; is Board Chair of Imagine Citizens’ Network (Alberta), and is member of the Board of Directors, Alberta Blue Cross. Stephen holds an Adjunct Faculty appointment in the Department of Community Health Sciences at the University of Calgary.

Stephen began his career in British Columbia, where he worked on strategic research, evaluation and policy initiatives at the community level and with the BC Ministry of Health, with a focus on HIV/AIDS and population health.

He has a Master’s degree in Sociology from Simon Fraser University in British Columbia. He is based in Edmonton, Alberta.

Dr. Kendall Ho’s academic and research interests fall into the domain of technology-enabled knowledge translation (TEKT) – the use of information technologies to accelerate the incorporation of the latest health evidence into routine practice. Specific directions within TEKT include telehealth, information and communication technologies (ICT) and patient safety, ICT and public engagement, and evidence-based policy translation in eHealth.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.